Matthews, E; Hartley, L; Sud, R; Hanna, MG; Muntoni, F; Munot, P; (2018) Acetazolamide can improve symptoms and signs in ion channel-related congenital myopathy. [Letter]. Journal of Neurology, Neurosurgery and Psychiatry 10.1136/jnnp-2017-317849.

Preview	Text (Article) Matthews_ACZ response myopathy JNNP final revisions clean 23 4 2018.pdf - Accepted Version Download (361kB) | Preview
Preview	Image (Supplementary information) Fig 1 ACZ response myopathy.jpg - Accepted Version Download (74kB) | Preview

Abstract

Sarcolemmal voltage-gated sodium and calcium ion channels are essential for generating action potentials and excitation contraction coupling required for muscle contraction. Autosomal dominant sodium and calcium ion channel gene disorders cause episodic symptoms of periodic paralysis (PP) and myotonia.1 Acetazolamide treatment improves these symptoms.2 Recently, recessive congenital myopathies due to compound heterozygous or homozygous ion channel gene mutations have been described with fixed muscle weakness and disability.3 4 In case series we previously reported, two individuals with ion channel-related congenital myopathy had additional discrete episodic or fluctuant weakness causing added morbidity.3 4 Here, we delineate the long-term benefit of treatment with acetazolamide for these individuals and discuss the implications for genetic diagnosis and management of future cases.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item